KEYWORDSSimple, sensitive and precise spectrophotometric and chemometric stability indicating techniques were adopted for Olanzapine (OLA) determination in presence of its degradation products over a concentration range of 0.002-0.02 mg/mL. The spectrophotometric technique involves six methods; first method is first derivative (D1) spectrophotometric one, which allows the determination of OLA in presence of its acidic and alkaline degradation products at 261.2 and 260.6 nm with mean percentage recoveries of 99.90±0.48 and 99.95±0.67, respectively. While second derivative spectrophotometry (D2) was used for determination of drug in presence of alkaline degradation products. Second method is firstderivative of the ratio spectra (DR1) for determination of OLA in presence of its acidic and alkaline degradation products at 267.9 and 251.6 nm, respectively with mean percentage recoveries of 99.81±0.64 and 100.53±1.11, respectively. The third method is pH-induced difference method for determination of OLA in presence of its acidic and alkaline degradation products; with mean percentage recoveries 100.09±0.06 and 99.77±0.78, respectively. Fourth method is the Q-analysis (absorption ratio) method, which involves the formation of absorbance equation at 296.3 nm (isosbestic point) and 271 nm (λmax of OLA) for the determination of OLA in presence of its acidic degradation products. The mean percentage recovery is 100.07±1.51. Fifth method based on dual wavelength selection was developed for the determination of OLA in presence of its acidic degradation products with mean percentage recovery of 100.36±0.69. Sixth method based on simple mathematic algorithm by the bivariate calibration was also used for the determination of OLA with the mean percentage recovery of 101.72±1.10. The second technique is chemometrics, which includes determination of OLA in presence of its acidic degradation products using multivariate calibration methods (the classical least squares (CLS), principle component regression (PCR) and partial least squares (PLS)) using the information contained in the absorption spectra.Olanzapine Q-absorbance Chemometrics Dual wavelength Bivariate calibration Derivative spectrophotometer

No abstract

Objectives: An ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay has been developed and validated for the quantification of oxycodone in rat serum and brain tissue homogenates. Methods: A simple extraction method using methyl-t-butyl ether was used for sample extraction with oxycodone-D3 as an internal standard (IS). A Symmetry ® C18 column (100 mm x 4.6 mm, 5 µm) connected to a Phenomenex Luna ® guard column (4 x 3 mm, 5 µm) was used for chromatographic separation. The mobile phase was composed of a mixture of acetonitrile and 0.1 % formic acid in water (pH = 2.7) (15:85, v/v). The flow rate was 0.4 mL/min, the total run time was 5 min, and the injection volume was 10 µL. The column and autosampler temperatures were maintained at 60 °C and 25 °C, respectively. Results: The calibration curve for oxycodone was linear over the range of 10-2000 ng/mL. Oxycodone extraction recovery from rat serum and brain samples ranged from 90.78-105.85 % and 98.42-104.38 % with relative standard deviation (RSD) values of 0.94-3.87 % and 1.04-2.82 %, respectively. The inter-day accuracy values ranged from 87.67-104.83 %, while the intra-day accuracy values ranged from 86.95-105.67 %. Conclusion: This method can be used for the quantification of oxycodone in samples obtained from preclinical animal studies and has great promise for applications in the quantification of oxycodone in human biological matrices.